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lsevier1. Introduction
Since last few decades, there is tremendous growth of research
in the synthesis of nitrogen containing heterocyclic derivatives
because of their utility in various applications, such as phar-
maceuticals, propellants, explosives, pyrotechnics and espe-
cially in chemotherapy (Chavez and Parrish, 2009). A large
number of ring systems containing 1,2,4-triazoles have been
incorporated into a wide variety of therapeutically interesting
drug candidates including anti-inﬂammatory, CNS stimulants,
sedatives, anti-anxiety, antimicrobial agents (Nadkarni et al.,
2001; Isloor et al., 2009), antimycotic agents such as Fluconaz-
ole, Itraconazole and Voriconazole (The Merck Index, 1996;
Haber, 2001). Also there are some known drugs containing
1,2,4-triazole moiety, e.g. Triazolam (Brucato et al., 1978),
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Scheme 1 Synthetic route for the Schiff bases 4a–f.
178 Y.J. Mange et al.Alprazalam (Coffen and Fryer, 1973), Etizolam (Shiroki et al.,
1975), Furacylin (Povelista and Gural, 1973), Ribavirin (Sid-
well et al., 1975), Hexaconazole (Shepherd, 1986), Triadimefon
(Lye, 1987), Mycobutanil (Efthimiadis, 1988), Rizatriptan (
Hart, 1999), Propiconazole (Reet et al., 1976), and Fluotrimaz-
ole (Worthington, 1984). 3-Substituted-4-amino-5-mercapto-
1,2,4-triazoles by virtue of their ambient nucleophilic centre
are good starting materials for the synthesis of several interest-
ing N-bridged heterocycles. A detailed literature survey re-
vealed that, Schiff bases possess diverse type of biological
activities (El-Sayed, 2006). Some Schiff’s bases bearing aryl
groups or heterocyclic residues exhibited interesting biological
activities, which has attracted many researchers’ attention in
recent years (Holla et al., 2000; Isloor et al., 2009; Marina
et al., 2002). Keeping in view of the above facts and in contin-
uation of our search on biologically potent molecules, we here-
in report the synthesis of some new 1,2,4-triazole derivatives
and their antimicrobial activity.
2. Experimental
2.1. Measurements
Melting points were determined by open capillary method and
are uncorrected. The IR spectra (in KBr pellets) were recorded
on a Thermo Nicolet avatar 330-FT-IR spectrophotometer. 1H
NMR and 13C NMR spectra were recorded (DMSO-d6) on a
Bruker (400 MHz) spectrometer using TMS as internal stan-
dard. Chemical shift values are given in d scales. The mass
spectra were recorded on LC–MS-Agilent 1100 series and
API 2000 LC/MS system. Elemental analyses were performed
on a Flash EA 1112 series CHNS–O analyzer. The completion
of the reaction was checked by thin layer chromatography
(TLC) on silica gel coated aluminium sheets (Silica Gel 60
F254). Commercial grade solvents and reagents were used
without further puriﬁcation. The reaction pathway has been
summarized in Scheme 1.2.2. Synthesis
2.2.1. Synthesis of N-[(4-amino-5-sulfanyl-4H-1,2,4-triazol-3-
yl)methyl]-4-substituted-benzamide 3a–b
An equimolar mixture of N-benzoylglycine/N-(p-tolyl)glycine
2a (0.01674 mol) and thiocarbohydrazide 1 (0.01674 mol) were
fused on oil bath for 1 h. Then the reaction mixture was cooled
and treated with a cold solution of 5% NaHCO3. The resulted
solid was ﬁltered, washed with water and recrystallised from
ethanol.
2.2.1.1. N-[(4-Amino-5-sulfanyl-4H-1,2,4-triazol-3-
yl)methyl]benzamide 3a (Hassan, 2009). Yield 63.63%, m.p.
279–280 C. IR (cm1) 3447, 3316 (N–H str), 3096 (C–H
str), 1652 (C‚O str), 1601 (C‚N). 1H NMR (DMSO-d6)
d = 13.58 (s, 1H, S–H), 8.95 (t, 1H, N–H), 7.46–7.88 (m,
5H, Ar-H), 5.61 (s, 2H, –NH2), 4.49 (d, 2H, –CH2). MS
(EI). m/z 250 [M+1].
2.2.1.2. N-[(4-Amino-5-sulfanyl-4H-1,2,4-triazol-3-yl)methyl]-
4-methylbenzamide 3b. Yield 46.90%, m.p. 220–221 C.
IR (cm1) 3321, 3258 (N–H str), 3079 (C–H str), 1682
(C‚O str), 1617 (C‚N). 1H NMR (DMSO-d6) d = 13.47
(s, 1H, S–H), 8.51 (t, 1H, N–H), 7.18–7.78 (m, 4H, Ar-H),
5.48 (s, 2H, –NH2), 4.51 (d, 2H, –CH2). MS (EI). m/z 264
[M+1].
2.2.2. Synthesis of N-[(4-{[(E)-substituted]amino}-5-sulfanyl-
4H-1,2,4-triazol-3-yl)methyl]-4-substituted-benzamide 4a–f
Equimolar mixture of N-[(4-amino-5-sulfanyl-4H-1,2,4-tria-
zol-3-yl)methyl]-4-substituted-benzamide 3a–b (0.0004 mol),
substituted benzaldehyde (0.0004 mol) and 2–3 drops of con-
centrated sulfuric acid in ethanol–dioxane mixture was re-
ﬂuxed for 6 h. The resulting solution was cooled to room
temperature and the precipitated solid was ﬁltered under suc-
tion, washed with cold ethanol and recrystallised from hot
ethanol.
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sulfanyl-4H-1,2,4-triazol-3-yl)methyl]benzamide 4a. Yield
88.88%, m.p. 276–279 C. IR (cm1) 3322 (N–H str), 3046
(C–H stretch), 1642 (C‚O str), 1596 (C‚N), 1277 (C‚S).
1H NMR (DMSO-d6) d = 13.99 (s, 1H, S–H), 10.4 (s, 1H,
N‚CH), 9.01 (t, 1H, N–H), 7.42–8.33 (m, 9H, Ar-H), 4.67
(d, 2H, –CH2).
13C NMR (DMSO-d6) d = 166.3, 161.8,
158.9, 149.4, 148.8, 138.1, 133.6, 131.4, 129.6, 128.2, 127.2,
124.0, 34.2. MS [EI] m/z 383 [M+1]. Elemental analysis
(C17H14N6O3S); calcd. C, 53.40; H, 3.69; N, 21.98; found C,
53.36; H, 3.72; N, 21.95%.
2.2.2.2. N-[(4-{[(E)-(4-Methoxyphenyl)methylidene]amino}-
5-sulfanyl-4H-1,2,4-triazol-3-yl)methyl]benzamide 4b. Yield
66.34%, m.p. 232–235 C. IR (cm1) 3282 (N–H str), 3057
(C–H stretch), 1641 (C‚O str), 1603 (C‚N), 1251 (C‚S).
1H NMR (DMSO-d6) d = 13.82 (s, 1H, S–H), 9.78 (s, 1H,
N‚CH), 8.97 (t, 1H, N–H), 7.04–7.84 (m, 9H, Ar-H), 4.60
(d, 2H, –CH2), 3.84 (s, 3H, –OCH3).
13C NMR (DMSO-d6)
d = 166.3, 163.2, 162.7, 161.6, 148.3, 133.7, 131.3, 130.6,
128.2, 127.2, 124.5, 114.5, 55.4, 34.3. MS [EI] m/z 368
[M+1]. Elemental analysis (C18H17N5O2S); calcd. C, 58.84;
H, 4.66; N, 19.06; found C, 58.80; H, 4.61; N, 19.09%.
2.2.2.3. 4-Methyl-N-[(4-{[(E)-(4-nitrophenyl)methyli-
dene]amino}-5-sulfanyl-4H-1,2,4-triazol-3-yl)methyl]benzam-
ide 4c. Yield 64.88%, m.p. 269–272 C. IR (cm1) 3318 (N–H
str), 3035.8 (C–H str), 1640 (C‚O str), 1603 (C‚N), 1276
(C‚S). 1H NMR (DMSO-d6) d = 13.99 (s, 1H, S–H), 10.41
(s, 1H, N‚CH), 8.93 (t, 1H, N–H), 7.24–8.34 (m, 8H, Ar-
H), 4.67 (d, 2H, –CH2), 2.33 (s, 3H, CH3).
13C NMR
(DMSO-d6) d = 166.2, 161.8, 158.8, 149.3, 148.8, 141.3,
138.1, 130.8, 129.6, 128.8, 127.2, 124.0, 34.2, 20.8. MS [EI]
m/z 397 [M+1]. Elemental analysis (C18H16N6O3S); calcd. C,
54.54; H, 4.07; N, 21.20; found C, 54.59; H, 4.01; N, 21.25%.
2.2.2.4. N-[(4-{[(E)-(4-Methoxyphenyl)methylidene]amino}-
5-sulfanyl-4H-1,2,4-triazol-3-yl)methyl]-4-methylbenzamide
4d. Yield 75.11%, m.p. 246–250 C. IR (cm1) 3283 (N–H str),
3053 (C–H stretch), 1634 (C‚O str), 1604 (C‚N), 1246
(C‚S). 1H NMR (DMSO-d6) d = 13.68 (s, 1H, S–H), 10.12
(s, 1H, N‚CH), 8.69 (t, 1H, N–H), 6.96–7.83 (m, 8H, Ar-
H), 4.62 (d, 2H, –CH2), 3.86 (s, 3H, –OCH3), 2.38 (s, 3H, –
CH3). MS [EI] m/z 382 [M+1]. Elemental analysis
(C19H19N5O2S); calcd. C, 59.82; H, 5.02; N, 18.36; found C,
59.78; H, 5.06; N, 18.31%.
2.2.2.5. N-[(4-{[(E)-(4-Chlorophenyl)methylidene]amino}-5-
sulfanyl-4H-1,2,4-triazol-3-yl)methyl]-4-methylbenzamide 4e.
Yield 62.10%, m.p. 257–258.5 C. IR (cm1) 3295 (N–H str),
3045 (C–H str), 1637 (C‚O str), 1585 (C‚N), 1274 (C‚S).
1H NMR (DMSO-d6) d = 13.94 (s, 1H, S–H), 10.08 (s, 1H,
N‚CH), 8.94 (t, 1H, N–H), 7.24–7.93 (m, 8H, Ar-H), 4.61
(d, 2H, –CH2), 2.33 (s, 3H, –CH3).
13C NMR (DMSO-d6)
d = 166.2, 161.7, 161.3, 148.6, 141.4, 137.2, 131.0, 130.9,
130.2, 129.2, 128.8, 127.3, 34.2, 20.9. MS [EI] m/z 386. MS
[EI] m/z 386 [M+1]. Elemental analysis (C18H16ClN5OS);
calcd. C, 56.03; H, 4.18; N, 18.15; found C, 56.07; H, 4.12;
N, 18.20%.
2.2.2.6. N-[(4-{[(E)-(3,4-Dimethoxyphenyl)methyli-
dene]amino}-5-sulfanyl-4H-1,2,4-triazol-3-yl)methyl]-4-meth-ylbenzamide 4f. Yield 81.62%, m.p. 231–235 C. IR (cm1)
3372 (N–H stretch), 3052 (C–H stretch), 1653 (C‚O str),
1595 (C‚N), 1259 (C‚S). 1H NMR (DMSO-d6) d = 13.88
(s, 1H, S–H), 9.82 (s, 1H, N‚CH), 8.92 (t, 1H, N–H), 7.06–
7.75 (m, 7H, Ar-H), 4.64 (d, 2H, –CH2), 2.33 (s, 3H, –CH3),
3.74 (s, 3H, –OCH3), 3.84 (s, 3H, –OCH3).
13C NMR
(DMSO-d6) d = 166.2, 163.0, 161.6, 152.7, 149.1, 148.4,
141.3, 131.0, 128.8, 127.3, 124.7, 124.6, 111.2, 108.8, 55.6,
55.3, 34.3, 20.9. MS [EI] m/z 412 [M+1]. Elemental analysis
(C20H21N5O3S); calcd. C, 58.38; H, 5.14; N, 17.02; found C,
58.41; H, 5.19; N, 17.07%.
2.3. Antimicrobial studies
All the newly synthesized compounds were evaluated for
their antimicrobial activities against various microorganisms
representing Gram-positive bacteria (Staphylococcus aureus
and Bacillus subtilis), Gram-negative bacteria (Escherichia
coli and Pseudomonas aeruginosa) and fungus (Candida albi-
cans), using the Minimum Inhibition Concentration (MIC)
method by the serial dilution technique (Mackie and Mc
Cartney, 1989). Several colonies of S. aureus, B. subtilis,
E. coli and P. aeruginosa were picked off a fresh isolation
plate and inoculated in corresponding tubes containing
5 mL of trypticase soya broth. The broth was incubated
for 6 h at 37 C until there was visible growth. Mc Farland
No.5 standard was prepared by adding 0.05 mL of 1% w/v
BaCl2Æ2H2O in Phosphate Buffered saline (PBS) to 9.95 mL
of 1% v/v H2SO4 in PBS. The growth of all the four cultures
was adjusted to Mc Farland No. 5 turbidity standard using
sterile PBS. This gives a 108 cfu/mL suspension. The working
inoculums of above mentioned four different microorganisms
containing 105 cfu/mL suspension was prepared by diluting
the 108 cfu/mL suspension, 103 times in trypticase soya
broth.
Antimicrobial suspension was prepared by dissolving
0.5 lg of each compound in 10 mL of trypticase soya broth
to get 50 lg/mL. This suspension was ﬁlter sterilized in syr-
inge ﬁlters. To prepare the dilutions in all, for each of the
eight anti-microbial compounds and standard antimicrobial
i.e. Ceftriaxone, 24 tubes of 5 mL capacity were arranged in
four rows with each row containing six tubes. Then 1.9 mL
of trypticase soya broth was added in the ﬁrst tube in each
row and 1 mL in the remaining tubes. Now, 100 ll of ﬁltered
anti microbial suspension was added to the ﬁrst tube in each
row and after mixing the content, 1 mL was serially trans-
ferred from these tubes to the second tube in each of the rows.
The contents in the second tube of each of the rows were
mixed and transferred to the third tube in each of the rows.
This serial dilution was repeated till the sixth tube in each
of the rows. This provided anti microbial concentrations of
50, 25, 12.5, 6.25, 3.125, 1.6125 lg/mL in the ﬁrst to sixth
tube, respectively, in each row. Finally, 1 mL of 105 cfu/mL
of S. aureus, B. subtilis, E. coli, P. aeruginosa and C. albicans
suspension were added to the ﬁrst, second, third and fourth
rows of tubes, respectively. Along with the test samples and
Ceftriaxone (standard), the inoculum control (without antimi-
crobial compound) and broth control (without antimicrobial
compound and inoculum) were maintained. All the test sam-
ple and control tubes were then incubated for 16 h at 37 C.
The results of the antimicrobial studies are summarized in
Table 1.
Table 1 Antimicrobial activity of newly synthesized compounds.
Compound
No.
Antibacterial (MIC, lg/mL) Antifungal (MIC,
lg/mL)
S. aureus B. subtilis E. coli P. aeruginosa C. albicans
4a 3.125 3.125 3.125 3.125 1.6125
4b 3.125 3.125 3.125 3.125 3.125
4c 3.125 3.125 3.125 3.125 3.125
4d 3.125 3.125 3.125 3.125 3.125
4e 3.125 3.125 3.125 3.125 3.125
4f 3.125 3.125 25.00 25.00 1.6125
Ceftriaxone
(standard)
3.125 1.6125 1.6125 1.6125 3.125
Inoculum
control
Growth in all
concentrations
Growth in all
concentrations
Growth in all
concentrations
Growth in all
concentration
Growth in all
concentrations
Broth control No growth No growth No growth No growth No growth
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3.1. Chemistry
Formation of N-[(4-{[(E)-substituted]amino}-5-sulfanyl-4H-
1,2,4-triazol-3-yl)methyl]-4-substituted-benzamide (4) was
conﬁrmed by recording their IR, NMR, mass spectra and ele-
mental analyses. IR spectrum of compound 4a showed absorp-
tion bands at 3322, 3046, 1642, 1596 and 1277 cm1 which is
due to the N–H, C–H, C‚O, C‚N and C‚S groups, respec-
tively. The 1H NMR spectrum of 4a showed a singlet at d 13.99
corresponds to S–H proton. A singlet at d 10.4 was due to
N‚CH proton. A triplet was observed at d 9.01 was due to
N–H attached to –CH2. The appearance of doublet at d 4.67
and multiplet at d 7.42–8.33 was due to –CH2 and aromatic
ring protons, respectively. Similarly the mass spectrum was re-
corded and reported as [M+1] values. For the compound 4a,
molecular weight 383 is consistent with the molecular formula
C17H14N6O3S. The values for the remaining compounds have
been presented under the experimental part.3.2. Antimicrobial activity
All the newly synthesized compounds were screened for their
antibacterial and antifungal activities. For antibacterial stud-
ies, microorganisms employed wereS. aureus, B. subtilis, E. coli
and P. aeruginosa. For antifungal studies, microorganism em-
ployed was C. albicans. Both antimicrobial studies were as-
sessed by Minimum Inhibition Concentration (MIC) method
by the serial dilution technique.
From the antimicrobial activity study, it was found that,
compounds4a–f exhibited the same activity as that of the stan-
dard drug Ceftriaxone against S. aureus and moderate activity
against other bacteriaB. subtilis, E. coli, P. aeruginosa and also
fungus C. albicans. The observed activity may be due to pres-
ence of chloro, methoxy and nitro groups in these compounds.
The antifungal activity of compounds 4a and 4f against C.
albicans was found to be higher than that for the standard
drug. However, remaining compounds exhibited same activity
as that of standard drug. The observed activity in 4a and 4f is
may be due to the presence of nitro group alone for the 4a, and
in 4f, it may be due to the number and orientation of methoxy
group.4. Conclusion
A novel series of Schiff bases bearing 1,2,4-triazole ring sys-
tems were synthesized. These were characterized by IR,
NMR, mass spectrometry study and elemental analyses. All
the compounds were screened for their antibacterial and anti-
fungal activity by serial dilution method. Compounds 4a–f
exhibited the same activity as that of the standard drug Ceftri-
axone against S. aureus. Compounds 4a and 4f have showed
excellent antifungal activity.Acknowledgements
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